| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000031335 |
| Receipt No. | R000035748 |
| Official scientific title of the study | A randomized control trial of herbal medicine for cancer patients that examined influence of IL-6 and cachexy. |
| Date of disclosure of the study information | 2018/02/16 |
| Last modified on | 2018/02/16 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | A randomized control trial of herbal medicine for cancer patients that examined influence of IL-6 and cachexy.
|
|
| Title of the study (Brief title) | Influence of the herbal medicine
|
|
| Region |
|
|
| Condition | ||
| Condition | colorectal cancer, pancreatic cancer
|
|
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Relative dose intensity of first line chemothrapy
|
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | MTD, RD,IL-6
|
| Key secondary outcomes | QOL Nutritional assessment
|
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Hochuekkitou, gosyajinnkigan, keisibukuryogan
|
|
| Interventions/Control_2 | control | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | "(1) Histological proven adenocarcinoma
(2) possible oral intake (3) unresectable corolectal and pancreatic cancer (4) KRAS mutation untested or negative or positive (5) PS 0-1 (6) Adequate organ function (7) Written informed consent from patients (8) Capcitabine + Oxalipltain + Bevacizumab regimen in patients with colorectal cancer (9) Gemcitabine + Nab-paclitaxel in patients with pancreatic cancer (10) Best surpotive care in study2" |
|||
| Key exclusion criteria | "(1) Synchronous or metachronous (within 5 years) malignancies except for carcinoma in situ or mucosal tumors curatively treated with local therapy.
(2) Past history of severe hypersensitivity to drugs (3) Body temperature of over 38 degrees Celsius or active infection (4) serious bone marrow suppression, a renal damage or a liver damage (5) Severe complications (6) Pregnant women, women with the possibility of the pregnancy, or men who want their partners to become pregnant (7) Psychological disorder (8) Patients judged inappropriate for the study by the physicians " |
|||
| Target sample size | 60 | |||
| Research contact person | |
| Name of lead principal investigator | Masahiro Gotou |
| Organization | Osaka Medical College Hospital
|
| Division name | Chemotherapy Center |
| Address | 2-7 Daigaku-machi, Takatsuki City, Osaka, Japan |
| TEL | 072-683-1221 |
| in2030@osaka-med.ac.jp | |
| Public contact | |
| Name of contact person | Toshifumi Yamaguchi |
| Organization | Osaka Medical College Hospital |
| Division name | Chemotherapy Center |
| Address | 2-7 Daigaku-machi, Takatsuki City, Osaka, Japan |
| TEL | 072-683-1221 |
| Homepage URL | |
| ctc008@osaka-med.ac.jp | |
| Sponsor | |
| Institute | Osaka Medical College Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Grants-in-Aid for Scientific Research
|
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035748 |